Cardiac Biomarkers Market Size & Outlook, 2026-2034

Cardiac Biomarkers Market Overview

The global cardiac biomarkers market size is valued at USD 26.5 billion in 2025 and is estimated to reach USD 89 billion by 2034, growing at a CAGR of 14.1% during the forecast period. Cardiac biomarkers are experiencing growth due to factors such as the high prevalence of acute coronary syndrome and technological advancements in the field of cardiac biomarkers.

Key Trends and Insights

• North America dominated the global cardiac biomarkers market, accounting for the largest revenue share of over 43.5% in 2025.
• Asia Pacific is expected to exhibit the fastest growth rate of 15.3% during the forecast period.
• By type, the troponin segment held the largest revenue share of over 35.3% in 2025.
• By application, the myocardial infarction segment is the fastest-growing,exhibiting a CAGR of 12.7% in 2025.
• By end use, the laboratory testingsegment held the largest revenue share of 59.2% in 2025.
• The U.S. dominates the North America cardiac biomarkers market with largest revenue share.

Market Revenue Figures

• 2025 Market Size: USD 26.5 billion
• 2034 Projected Market Size: USD 89 billion
• CAGR (2026-2034): 14.1%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

Cardiac biomarkers are enzymes, proteins, and hormones released into the bloodstream during heart damage, helping to detect conditions such as myocardial infarction. The rising demand for point-of-care (POC) cardiac testing kits, valued for their fast and accurate results, is accelerating market growth. Technological integration, including AI and machine learning, enhances diagnostic precision, monitoring, and interpretation, further supporting adoption. Cardiac test kits with multi-parameter panels enable the rapid detection of abnormalities, reduce diagnostic delays, and enhance clinical decision-making in emergencies. Overall, fast diagnostics and advanced technologies continue to drive the market.

Latest Market Trends

Shift Toward Personalised Medicine in Cardiology

A major trend shaping the cardiac biomarkers market is the move toward personalised medicine, where treatments are tailored to a patient’s genetic and biomarker profile. Biomarkers enable the early identification of high-risk individuals and guide the selection of therapy, thereby improving outcomes. For instance, NT-proBNP levels help optimise treatment strategies in heart failure patients. As healthcare increasingly focuses on precision approaches, investment in innovative biomarkers is rising to support individualised cardiac care. This shift enhances clinical accuracy, reduces adverse events, and strengthens long-term disease management.

Growing Use of Multi-Biomarker Panels

Multi-biomarker panels are gaining traction as healthcare providers seek faster and more precise cardiac diagnostics. These panels combine markers such as troponin, BNP/NT-proBNP, CK-MB, myoglobin, and inflammatory proteins to improve diagnostic sensitivity and specificity. They reduce uncertainty in identifying acute coronary syndromes and heart failure while enabling better risk-stratification in emergency settings. Their compatibility with point-of-care platforms and AI-based interpretation further boosts clinical efficiency. As hospitals prioritise comprehensive and reliable testing, these multiplex panels are seeing wider adoption, strengthening their role in precision cardiovascular care and supporting earlier intervention and improved patient outcomes.

To get more insights about this report Download Free Sample Report

Market Driver

Increasing prevalence of cardiovascular diseases

Rising global rates of cardiovascular diseases are a key driver of market growth. Conditions such as peripheral arterial disease, myocardial infarction, and ischemia are increasing due to risk factors including diabetes, obesity, smoking, high cholesterol, and hypertension. In countries like the US, millions of adults are affected, creating a strong demand for accurate diagnostic tools. Hospital laboratories are increasingly relying on biomarkers such as myoglobin, natriuretic peptides, and ischemia-modified albumin for the rapid detection of cardiac dysfunction and patient-specific treatment planning. As personalised medicine becomes more central to clinical care, the need for reliable biomarkers to guide diagnosis and therapy continues to expand.

Market Restraint

Shortage of skilled Clinicians

A significant constraint on market growth is the global shortage of skilled cardiologists and trained clinicians. Factors such as healthcare system consolidation, reduced funding for medical training, certification burdens, and declining reimbursements limit the availability of specialists. Meanwhile, the prevalence of CVD risk factors, high cholesterol, obesity, inactivity, hypertension, and smoking, continues to rise, increasing diagnostic demand. Workforce shortages hinder the timely diagnosis and management of conditions detected through biomarkers such as myoglobin, natriuretic peptides, and ischemia-modified albumin. This imbalance between the rising disease burden and limited clinical expertise restricts the optimal utilisation of advanced biomarker tests and slows market expansion.

Market Opportunity

Growing Research and Development

Expanding R&D activities present major opportunities for the cardiac biomarkers market. The rising global burden of CVD is driving research into early detection tools, novel biomarkers, and advanced diagnostic technologies. Emerging markets, such as microRNAs, genetic variants, and metabolomic indicators, offer potential to transform cardiac diagnosis and risk prediction. Established biomarkers are being studied for additional pathways, including inflammation, oxidative stress, and fibrosis. Innovation in devices aims to lower testing costs while improving accuracy and speed. As biomarker science rapidly evolves, discoveries and technology-driven solutions are expected to enhance treatment outcomes and unlock significant market growth potential.

Regional Analysis

North America holds a 43.5% share of the global cardiac biomarkers market, supported by advanced healthcare infrastructure, early technology adoption, and a high cardiovascular disease burden. The U.S. drives regional dominance, with CVD accounting for about 25% of all deaths according to CDC data, creating strong demand for rapid and accurate diagnostics. The widespread use of high-sensitivity assays, integration of AI-enabled interpretation tools, and growing emphasis on preventive cardiology are further accelerating adoption. Robust R&D funding, presence of major diagnostic manufacturers, and rapid uptake of point-of-care solutions contribute to North America’s sustained leadership in the cardiac biomarkers industry.

• The U.S. leads North America’s cardiac biomarkers market, holding the largest revenue share and expected to grow at the fastest rate. High CVD prevalence, strong clinical guidelines advocating biomarker use, and integration of diagnostics into personalized medicine strategies fuel growth. Expanding hospital networks, advanced laboratory capabilities, and rising demand for remote and PoC diagnostics further enhance market penetration. Continuous innovation, strong regulatory frameworks, and active clinical research maintain the U.S. as a global biomarker adoption hub.

Asia Pacific Market Insights

Asia Pacific is poised for fastest growth at a CAGR of 15.3% due to rising geriatric populations, escalating CVD incidence, increasing R&D investments, and improving healthcare infrastructure. China alone reports over 330 million individuals with CVD, including millions with coronary artery disease and heart failure. India saw a 12.5% increase in heart-attack-related deaths in 2022, while Japan reports heart disease as the second leading cause of mortality. These trends underscore the need for early detection, rapid diagnostic tools, and high-sensitivity biomarker testing. Government initiatives, expanding hospital systems, and strategic industry collaborations are accelerating adoption across the region.

• China held the largest revenue share in Asia Pacific in 2025, driven by rapid advancements in diagnostic technologies and growing healthcare modernization. Rising CVD prevalence is accelerating adoption of high-sensitivity biomarker assays. Companies such as Mindray are expanding capabilities by launching innovations like hs-cTnI and NT-proBNP tests, enabling faster diagnosis, improved risk stratification, and better therapeutic monitoring.

Europe Market Insights

Europe constitutes the second-largest market, supported by strong academic research, established diagnostic manufacturers, and extensive healthcare networks. Collaborative efforts between universities, hospitals, and industry players are driving biomarker innovation, validation studies, and regulatory approvals. Government-funded R&D programs and national awareness initiatives are promoting early detection and adoption of cardiac biomarker testing. The region’s emphasis on high-quality diagnostic standards and evidence-based clinical practice continues to strengthen Europe’s overall market position.

• Germany represents one of Europe’s strongest cardiac biomarker markets due to its advanced diagnostic ecosystem and rapid adoption of point-of-care testing. High-sensitivity troponin assays, multi-biomarker panels, and rapid PoC platforms are widely integrated into clinical pathways for early cardiac disease detection. Supportive reimbursement structures, stringent regulatory standards, and nationwide screening initiatives encourage testing expansion.

Latin America Market Insights

Latin America’s market is expanding steadily, driven by rising CVD incidence and increasing demand for early, accurate diagnostics. CVD accounts for over 30% of deaths in the region, with limited rural diagnostic access accelerating the need for cost-effective biomarker solutions. Adoption of high-sensitivity troponin assays, expanding central-lab immunoassay capabilities, and deployment of PoC devices in emergency settings are strengthening market penetration. Growing government and private investments in cardiovascular care will continue to support market growth across Latin America.

• Brazil dominates the Latin American cardiac biomarkers market owing to its large population, developed healthcare infrastructure, and high CVD burden. Increased hospital capacity, rising diagnostic awareness, and integration of high-sensitivity troponin and other biomarker assays in clinical guidelines are driving growth. Strong investments in public and private healthcare, expansion of emergency care networks, and adoption of PoC devices are improving diagnostic reach.

Middle East and Africa Market Insights

The Middle East and Africa region is witnessing growing demand for cardiac biomarker testing due to rising CVD prevalence linked to urbanization, sedentary lifestyles, and high diabetes incidence. Governments across Saudi Arabia, UAE, and South Africa are investing heavily in healthcare modernization, expanding diagnostic capacity, and improving access to early detection tools. Regional health strategies and public awareness campaigns aimed at reducing cardiac mortality are accelerating biomarker uptake, positioning MEA as an emerging growth market with expanding opportunities.

• The UAE is one of MEA’s fastest-growing cardiac biomarker markets, supported by advanced healthcare infrastructure and strong government investment. High-sensitivity troponin assays and multi-biomarker panels are increasingly used across hospitals, reflecting high clinical readiness and modern diagnostic capabilities. Favorable reimbursement policies, rising clinician awareness, and national initiatives promoting early cardiovascular screening support rapid adoption.

Type Insights

The troponin segment accounted for over 35.3% of global revenue in 2025. Its dominance stems from exceptional diagnostic accuracy, high specificity, and strong predictive value for cardiac events. As myocardial infarction and stroke incidence continue to rise, troponin testing remains the gold standard for early detection. Growing clinical reliance, wider use in emergency care, and availability of high-sensitivity assays further strengthen its adoption across global healthcare systems.

The CK-MB segment is the fastest-growing, with a CAGR of 11.8%, driven by advancements in rapid and multiplex point-of-care technologies. Innovations such as paper-based fluorescence vertical flow assays (fxVFA) integrated with deep-learning algorithms enable the simultaneous detection of CK-MB, myoglobin, and FABP within minutes using minimal serum volume. As demand for quick and accurate triage rises, CK-MB testing continues to complement troponin assays in broader cardiac diagnostic workflows.

Application Insights

Acute coronary syndrome led the market in 2025, holding a revenue share of 47.4%. Rapid urbanisation, sedentary lifestyles, and rising disease burden, especially in low- and middle-income economies, are significantly increasing ACS incidence. Cardiac troponin T and I remain the preferred diagnostic biomarkers due to their superior sensitivity and early detection capability. With growing hospital admissions for chest pain and the need for rapid diagnostics, ACS continues to drive substantial demand for advanced biomarker testing.

The myocardial infarction segment is the fastest-growing, exhibiting a CAGR of 12.7% as global incidence surges and research activity intensifies. New biomarker-based prediction models are improving early MI detection. The expansion of biomarker validation studies, integration of multi-omics, and a heightened focus on early risk assessment are collectively driving the adoption of biomarker-driven MI diagnostics in clinical practice.

End-User Insights

Laboratory testing dominated the market, accounting for a 59.2% share in 2025, primarily due to the availability of sophisticated instruments, skilled personnel, and highly controlled testing environments. Patients experiencing cardiovascular symptoms commonly visit healthcare facilities where laboratory-based tests provide precise and reliable results essential for an accurate diagnosis. Established workflows, strong clinician trust, superior analytical sensitivity, and broad test menus ensure laboratories remain the most preferred setting for comprehensive cardiac biomarker evaluation across hospitals and diagnostic centres.

The point-of-care (PoC) testing segment is projected to grow at the fastest rate, exhibiting a CAGR of 14%, fueled by rising emergency department visits, expanding geriatric populations, and supportive government initiatives. PoC devices offer rapid turnaround times, enabling immediate clinical decisions, especially in suspected cardiac arrest or acute chest pain cases. Advancements in portable analysers, miniaturised assays, and connectivity with digital health platforms are further accelerating adoption.

Competitive Landscape

The cardiac biomarkers market is moderately consolidated, with a few global diagnostics giants, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers, holding significant market share due to strong assay portfolios, advanced analyzer platforms, and large global distribution networks. Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers are key players driving innovation in the cardiac biomarkers market. Roche Diagnostics offers a wide range of cardiac biomarkers, including troponin tests, which are essential for diagnosing myocardial infarction.

List of key players in Cardiac Biomarkers Market

1. Roche Diagnostics
2. Abbott Laboratories
3. Siemens Healthineers
4. Ortho Clinical Diagnostics
5. Beckman Coulter (Danaher Corporation)
6. Thermo Fisher Scientific
7. BioMérieux
8. SeraCare Life Sciences
9. Randox Laboratories
10. Quidel Corporation
11. Hoffmann-La Roche AG
12. Hologic, Inc.
13. Johnson & Johnson Services Inc.
14. Trivitron Healthcare
15. ACS Biomarker B.V.
16. Novartis AG

To get more findings about this report Download Market Share

Strategic Initiatives

• June 2025 - Cumberland Pharmaceuticals presented positive Phase 2 results for Ifetroban (oral therapy for Duchenne muscular dystrophy, DMD) at the Parent Project Muscular Dystrophy (PPMD) conference. The data showed improved left ventricular ejection fraction (LVEF) and a decrease in damaged cardiac biomarkers (NT-proBNP and Troponin I), clinically validating the use of these cardiac markers as endpoints for therapy evaluation.
• June 2025 - The UP STEMI Care Program was launched by the government to enhance emergency heart care in rural and semi-urban areas in SGPGIMS. To decrease the ST-Elevation Myocardial Infarction (STEMI) death rates, which is one of the most lethal and time-sensitive types of heart attack, is the main goal of this initiative, and will detect heart attacks with the help of tele-ECG technology in remote regions within minutes.
• January 2025 - BioMérieux entered into an agreement to acquire SpinChip Diagnostics ASA, a privately held Norwegian diagnostics company. SpinChip has developed a groundbreaking immunoassay diagnostics platform, featuring a small benchtop analyzer designed for near-patient testing.